Watch our webinar with ImpediMed, featuring Managing Director & CEO Dr Parmjot Bains. A presentation followed by live Q&A with the audience.

ImpediMed is an ASX listed, leading global medical technology company that designs and manufactures medical devices that employ bioimpedance spectroscopy (BIS) technology for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients. With its SOZO® Digital Health Platform and BIS screening technology, ImpediMed is the only company to offer an FDA-cleared device for multiple disease conditions utilizing BIS technology. ImpediMed’s initial efforts are directed toward Cancer Survivorship with a particular focus on the detection and prevention of breast cancer related lymphoedema. The company continues to forge new standards of care in fluid and body composition management with potential applications in the treatment and detection of Heart Failure, Renal Failure, Protein Calorie Malnutrition and further cancer survivorship through monitoring muscle and bone loss.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.